Clinical trials: Diabetes, open to volunteers
Type 1 Diabetes
Early Detection of Type 1 Diabetes in First Degree Relatives of Type 1 Diabetes Patients (DETECT T1D GULF)
The aim of this research is to identify pre-symptomatic Type 1 Diabetes (T1D) in young children and adolescents who have first degree relatives with T1D.
- Trial name
- NCT07038473
- Testing
- Investigational Procedure
- Where
- 7 sites in Kuwait, Saudi Arabia and 1 more
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
The goal of this clinical trial is to determine whether Endoscopic Sleeve Gastroplasty (ESG)-induced weight loss can improve glycemic outcomes and alter the trajectory toward insulin dependence in adults with obesity and…
- Trial name
- MEASURE (NCT07639684)
- Testing
- ESG with OverStitch
- Volunteers
- 50 people
- Sponsor
- Boston Scientific Corporation
Antiphospholipid (aPL)-Positive, Rheumatic Arthritis
MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)
The primary objective of this multicenter observational registry is to characterize the clinical, epidemiological, and biological profiles of individuals of Middle Eastern, North African, and Levantine ancestry, including…
- Conditions
- Antiphospholipid (aPL)-Positive, Rheumatic Arthritis, Celiac Disease, Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- MERIT (NCT07892651)
- Where
- Jordan
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Axiom Bioregistry
Type 2 Diabetes Mellitus
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with T2DM and increased cardiovascular risk that is inadequately managed alone or on stable…
- Trial name
- Eluminate-2 (NCT07662213)
- Testing
- Elecoglipron, Semaglutide
- Where
- 210 sites in United States, Argentina and 13 more
- Volunteers
- 1,200 people
- Sponsor
- AstraZeneca
Colon Cancer
Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer
The goal of this clinical trial is to learn if giving two medicines together, porustobart and pembrolizumab, before surgery can treat a common type of colon cancer called microsatellite stable (MSS) colon cancer in adults.
- Trial name
- NCT07808151
- Testing
- Pembrolizumab, Porustobart
- Where
- 30 sites in United States, Belgium and 4 more
- Volunteers
- 100 people
- Sponsor
- Solstice Oncology, Inc.
Diabetes (DM)
Randomized Trial of the RIGHTEST iFree 2 CGM System for Glycemic Control in Adults With Diabetes Mellitus
The goal of this clinical trial is to find out whether using a real-time continuous glucose monitoring (CGM) system can improve daily blood sugar control compared with usual self-monitoring of blood glucose (SMBG; finger-stick…
- Trial name
- NCT07889375
- Testing
- Continuous Glucose Monitoring (CGM), Self-monitoring of blood glucose (SMBG)
- Where
- Taiwan
- Volunteers
- 324 people
- Sponsor
- Bionime Corporation
Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Type 2
RIGHTEST iFree 2 CGM in Pregnant Women With Diabetes Study
This study will evaluate the accuracy and safety of the RIGHTEST iFree 2 Continuous Glucose Monitoring (CGM) System in pregnant women with type 1 diabetes, type 2 diabetes, or gestational diabetes.
- Conditions
- Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Type 2, Diabetes, Gestational
- Trial name
- NCT07889388
- Testing
- RIGHTEST iFree 2 Continuous Glucose Monitoring System
- Where
- Germany
- Volunteers
- 104 people
- Sponsor
- Bionime Corporation
Type 1 Diabetes Mellitus
A Phase 2 Two-Part Study of Oral PS1 in Healthy Volunteers and Adults With Newly Diagnosed Type 1 Diabetes
This study consists of 2 sub-studies, including Part A and Part B. Part A is intended to further characterize the pharmacokinetic (PK) profile of PS1 based on existing single ascending dose (SAD) and multiple ascending dose (MAD)…
- Trial name
- NCT07889505
- Testing
- PS1
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Pharmasaga Co. Ltd.
Type 2 Diabetes Mellitus
A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering Medications
The study will evaluate the efficacy and safety of enicepatide, a glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor (GLP-1/GIP) receptor agonist (RA), compared with tirzepatide among participants with…
- Trial name
- ENI-SPIRE-2 (NCT07889648)
- Testing
- Enicepatide, Tirzepatide
- Volunteers
- 948 people
- Sponsor
- Hoffmann-La Roche
Type 2 Diabetes, Chronic Kidney Disease (CKD) Stages G2 to G3b
A Study to Learn More About How Well Finerenone Works in Real-world in People With Type 2 Diabetes and Chronic Kidney Disease in Primary Care (IMSS= Instituto Mexicano Del Seguro Social)
The main purpose of this study is to learn how treatment with finerenone affects the urinary albumin-to-creatinine ratio (uACR), a marker of kidney health, over time in adults with type 2 diabetes and chronic kidney disease who…
- Trial name
- FINE-IMSS-MX (NCT07841015)
- Testing
- Finerenone
- Where
- Mexico
- Volunteers
- 800 people
- Sponsor
- Bayer
Pre Diabetes
Effects of Mango on Insulin Sensitivity in Prediabetes
The purpose of this study is to determine whether daily mango consumption for 6 weeks can improve glucose utilization in individuals with prediabetes.
- Trial name
- MG4 (NCT07886372)
- Testing
- Mango juice, Control Beverage
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Hypertension, Vascular Diseases
SPYRAL GEMINI Pilot Study
The purpose of the SPYRAL GEMINI Pilot Study is to evaluate that multi-organ denervation with the Gemini System is safe and provide evidence of blood pressure reduction when studied in an uncontrolled hypertensive population with…
- Conditions
- Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases
- Trial name
- SPYRAL GEMINI (NCT06907147)
- Testing
- Multi-Organ Denervation Gemini System
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 175 people
- Sponsor
- Medtronic Vascular
Type 1 Diabetes (T1D), Type 1 Diabetes Mellitus
A Study of GNTI-122 in Adults Recently Diagnosed With T1D
This is a 78-week single arm, multi-center, Phase 1 study to evaluate the safety, tolerability, cellular kinetics, and biomarker changes in C-peptide over time of GNTI-122, an investigational cell therapy manufactured from a…
- Trial name
- POLARIS (NCT06919354)
- Testing
- GNTI-122
- Where
- 10 sites in United States
- Volunteers
- 16 people
- Sponsor
- GentiBio, Inc
Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM
- Trial name
- NCT07465224
- Testing
- ALN-4324
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Alnylam Pharmaceuticals
Type 2 Diabetes
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
This is a phase 2 randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of icovamenib in participants with Type 2 Diabetes (T2D) not achieving glycemic targets despite GLP-1-based therapy.
- Trial name
- NCT07502508
- Testing
- icovamenib 100 mg
- Where
- 20 sites in United States
- Volunteers
- 60 people
- Sponsor
- Biomea Fusion Inc.
Diabetes Insipidus
A Study in Adult Males With X-linked Congenital Nephrogenic Diabetes Insipidus to Test the Effects of NDI-5001 Given for Multiple Days and to Test How NDI-5001 is Tolerated and Taken up in the Body
The primary purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NDI-5001 administered as a capsule following daily oral dosing in adult males with X-linked congenital…
- Trial name
- NCT07525960
- Testing
- NDI-5001
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Obesity, Overweight
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM.
- Conditions
- Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus
- Trial name
- NCT07654374
- Testing
- aleniglipron
- Where
- 74 sites in United States
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Breast Cancer, Diabetes Type II
A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes
This study will evaluate the safety of inavolisib in combination with fulvestrant, with or without palbociclib, in participants with PIK3CA-mutated, HR+, HER2-negative ABC and type 2 diabetes.
- Trial name
- NCT07748208
- Testing
- Inavolisib, Fulvestrant, Palbociclib
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 40 people
- Sponsor
- Hoffmann-La Roche
Type 1 Diabetes, Type 2 Diabetes
Evaluation of MiniMed Next Generation Extended Wear Sensors and Algorithm in Patients With Type 1 and Type 2 Diabetes
This study will collect sensor data in subjects with T1D or T2D, 2-80 years of age.
- Trial name
- NCT07864168
- Testing
- Next Generation Extended Wear Sensors
- Where
- 18 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Medtronic MiniMed, Inc.
Obesity, Overweight
A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes
The main purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight with or without Type 2 Diabetes.
- Conditions
- Obesity, Overweight, Diabetes Mellitus, Type 2
- Trial name
- NCT07881887
- Testing
- LY4167586
- Where
- 12 sites in United States, Singapore
- Volunteers
- 617 people
- Sponsor
- Eli Lilly and Company